CSIR launches ayurvedic anti diabetic drug BGR-34
A scientifically confirmed anti-diabetes herbal drug, known as 'BGR-34′, was released by a Council of Scientific and Industrial Research (CSIR) lab in Lucknow, India on 25th of October 2015. A combo of natural ingredients from plants, the drug is based on Ayurveda and has no side effects. The drug is for control of type-II diabetes mellitus.
The drug has been collectively formulated by two CSIR laboratories, National Botanical Research Institute (NBRI) and Central Institute for Medicinal and Aromatic Plant (CIMAP). It was released on the 62nd annual day of the NBRI for commercial production and marketing by M/s Aimil Pharamaceuticals Pvt Ltd, New Delhi.
Senior principal scientist of NBRI, Dr. AKS Rawat said, "The drug has ingredients from 4 plants described in Ayurveda and that makes it safe." It has been examined on animals and scientific study has identified it safe and effective, with clinical studies demonstrating 67% success.
The medicine enhances immune system, performs as anti-oxidant and checks free radicals. Although there are other anti diabetes herbal medicines in the market, 'BGR-34′ has been confirmed scientifically.
The medicine will help manage normal blood glucose levels, decrease chances of problems because of chronic high blood glucose levels and provide a good quality life to sufferers with high blood sugar levels.
The formulation was released previously by the Vice-President Hamid Ansari in February 2014 at New Delhi, but on 25th, the product was launched commercially.
V S Kapoor, marketing head of Aimil Pharmaceuticals said, "We will manufacture it now and it will be accessible in market soon, might be in the coming two weeks." It will be offered in the form of tablets and may price Rs 500 for 100 tablets.
The drug has been collectively formulated by two CSIR laboratories, National Botanical Research Institute (NBRI) and Central Institute for Medicinal and Aromatic Plant (CIMAP). It was released on the 62nd annual day of the NBRI for commercial production and marketing by M/s Aimil Pharamaceuticals Pvt Ltd, New Delhi.
Senior principal scientist of NBRI, Dr. AKS Rawat said, "The drug has ingredients from 4 plants described in Ayurveda and that makes it safe." It has been examined on animals and scientific study has identified it safe and effective, with clinical studies demonstrating 67% success.
The medicine enhances immune system, performs as anti-oxidant and checks free radicals. Although there are other anti diabetes herbal medicines in the market, 'BGR-34′ has been confirmed scientifically.
The medicine will help manage normal blood glucose levels, decrease chances of problems because of chronic high blood glucose levels and provide a good quality life to sufferers with high blood sugar levels.
The formulation was released previously by the Vice-President Hamid Ansari in February 2014 at New Delhi, but on 25th, the product was launched commercially.
V S Kapoor, marketing head of Aimil Pharmaceuticals said, "We will manufacture it now and it will be accessible in market soon, might be in the coming two weeks." It will be offered in the form of tablets and may price Rs 500 for 100 tablets.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.